



IROC Resources Handout

Main IROC Website: <https://www.irocqa.org/>

IROC Mission: *to provide integrated radiation oncology and diagnostic imaging quality control programs in support of the National Cancer Institute's National Clinical Trials Network thereby assuring high quality data for clinical trials designed to improve the clinical outcomes for cancer patients worldwide.*


NCI Resources:

NCI Cancer Therapy Evaluation Program (CTEP): <https://ctep.cancer.gov/>

NCI Community Oncology Research Program (NCORP): <https://ncorp.cancer.gov/>

NCI Experimental Therapeutics Clinical Trial Network (ETCTN):
<https://ctep.cancer.gov/initiativesprograms/etctn.htm>

NCI National Clinical Trial Network (NCTN): <https://www.cancer.gov/research/infrastructure/clinical-trials/nctn>



Clinical Trial Groups:

Alliance for Clinical Trials in Oncology: <https://www.allianceforclinicaltrialsinoncology.org/main/>

Children's Oncology Group (COG): <https://childrensoncologygroup.org/>

ECOG-ACRIN Cancer Research Group: <https://ecog-acrin.org/>

NRG Oncology: <https://www.nrgoncology.org/>

SWOG Cancer Research Network: <https://www.swog.org/>

Canadian Cancer Trials Group: <https://www.ctg.queensu.ca/>

Clinical Trial Support Sites:

Cancer Trials Support Unit (CTSU) – protocol documents: <https://ctsu.org/>

TRIAD – clinical trial image exchange application: <https://triadhelp.acr.org/>

Center for Innovation in Radiation Oncology (CIRO) – contouring atlases, protocol templates, presentations: <https://www.nrgoncology.org/About-Us/Center-for-Innovation-in-Radiation-Oncology>

Qualification Utility for Imaging CoreLab (QUIC): <https://quic.acr.org/>

ACR Clinical Resources: <https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards>



References:

FitzGerald TJ. A new model for imaging and radiation therapy quality assurance in the National Clinical Trials Network of the National Cancer Institute. *Int J Radiat Oncol Biol Phys*. 2014 Feb 1;88(2):272-3. doi: 10.1016/j.ijrobp.2013.09.030. PMID: 24411600.

Molineu A, Followill DS, Balter PA, Hanson WF, Gillin MT, Huq MS, Eisbruch A, Ibbott GS. Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys*. 2005 Oct 1;63(2):577-83. doi: 10.1016/j.ijrobp.2005.05.021. PMID: 16168849.

Taylor PA, Lowenstein J, Followill D, Kry SF. The Value of On-Site Proton Audits. *Int J Radiat Oncol Biol Phys*. 2022 Mar 15;112(4):1004-1011. doi: 10.1016/j.ijrobp.2021.10.145. Epub 2021 Nov 13. PMID: 34780973; PMCID: PMC8863623.

Mayo CS, et al. American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology. *Int J Radiat Oncol Biol Phys*. 2018 Mar 15; 100(4): 1057-1066. <https://doi.org/10.1016/j.ijrobp.2017.12.013>.

Link to supplements: https://www.aapm.org/pubs/reports/RPT_263_Supplemental/

Garin E, et al. DOSISPHERE-01 Study Group. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. *Lancet Gastroenterol Hepatol*. 2021 Jan;6(1):17-29. doi: 10.1016/S2468-1253(20)30290-9. Epub 2020 Nov 7. PMID: 33166497.

Mir R, Kelly SM, Xiao Y, Moore A, Clark CH, Clementel E, Corning C, Ebert M, Hoskin P, Hurkmans CW, Ishikura S, Kristensen I, Kry SF, Lehmann J, Michalski JM, Monti AF, Nakamura M, Thompson K, Yang H, Zubizarreta E, Andratschke N, Miles E. Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines. *Radiother Oncol*. 2020 Sep;150:30-39. doi: 10.1016/j.radonc.2020.05.038. Epub 2020 Jun 3. PMID: 32504762.

Allen B, Levin DC, Brant-Zawadzki M, Lexa FJ, Duszak R, ACR White Paper: Strategies for Radiologists in the Era of Health Care Reform and Accountable Care Organizations: A Report From the ACR Future Trends Committee, *JACR*, 8(5):309–317 (2011), ISSN 1546-1440, <https://doi.org/10.1016/j.jacr.2011.02.011>

Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, Mooney MM. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? *J Clin Oncol*, 26(22):3791–3796 (2008). <https://doi.org/10.1200/JCO.2008.16.1711>